Alabama compounder slapped with FDA warning letter

FDA sign

Eagle Pharmacy, an Alabama drug compounder, was slapped with a warning letter by the FDA for unsanitary conditions and failing to register new compounds.

The letter, which was posted on the FDA’s website, cited the Hoover, AL-based compounder for “serious deficiencies” in its manufacturing process. During an August 2015 inspection, the regulatory agency observed an employee “moving their arm over open vials during aseptic filling.”

The inspector also saw an employee place materials onto a critical work surface without first disinfecting the materials. Additionally, media plates used for personnel and environmental monitoring didn’t contain disinfectant neutralizers, which could potentially bias results.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

The agency also cited Eagle Pharmacy for failing to show correct procedures to ensure its products are produced in a sterile environment, which poses a risk of contamination.

The company was also cited for not having FDA-approved applications for drug products and misbranding its compounded products.

The agency noted in its warning that some of Eagle’s responses to the inspection fell short of FDA regulations and without prompt action the company could face legal action, including seizure of the facility. It said it will re-inspect the site.

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.